<DOC>
	<DOCNO>NCT02239380</DOCNO>
	<brief_summary>The purpose study determine efficacy , safety pharmacokinetics Lorazepam Japanese patient Status Epilepticus Repetitive Status Eplilepticus .</brief_summary>
	<brief_title>Lorazepam Treatment Status Epilepticus Repetitive Status Epilepticus Japan</brief_title>
	<detailed_description />
	<mesh_term>Status Epilepticus</mesh_term>
	<mesh_term>Lorazepam</mesh_term>
	<criteria>Subjects status epilepticus repetitive status epilepticus / cluster seizure seizures evaluate investigator 's visual observation base motor symptom seizure evaluate EEG . Subjects status epilepticus accompany generalized seizure , partial seizure secondarily generalized seizure last 5 minute longer Subjects repetitive status epilepticus / cluster seizure accompany less 3 consecutive episode generalized seizure , partial seizure secondarily generalize seizure 1 hour . Subjects young 3 month ( either gender eligible study ) Subjects know suspected recurrent seizure due illegal drug alcohol withdrawal Subjects known history hypersensitivity lorazepam benzodiazepine Subjects know history benzodiazepine abuse . Subjects currently receive lorazepam Subjects angleclosure glaucoma Subjects myasthenia gravis Subjects either aspartate transaminase , alanine transaminase , total bilirubin , blood urea nitrogen , creatinine screen visit exceed 2x upper limit normal institutional reference value ( data available ) Subjects white blood cell count le 3000/mm3 neutrophil count le 1500/mm3 screen visit ( data available )</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Lorazepam</keyword>
	<keyword>Status Epilepticus</keyword>
</DOC>